Methods and compositions for treating cerebral amyloid angiopathy
AssigneeNew York University
InventorThomas Wisniewski
Life of this patent
Estimating the term…
Abstract
The present application discloses a method of inhibiting the onset of cerebral amyloid angiopathy (CAA) and associated conditions in a subject including administering, to a subject at risk of developing CAA, an antibody-based molecule that binds to GPIIIa49-66 on activated platelets, under conditions effective to inhibit formation of platelet micro-clots, thereby inhibiting the onset of CAA and associated conditions. Also described is a method of reducing cerebral vascular platelet micro-clots in a subject in need thereof and a combination therapeutic that includes an antibody-based molecule that binds to GPIIIa49-66 on activated platelets, and an Alzheimer's disease therapeutic.
Claims13
A method of inhibiting the onset of cerebral amyloid angiopathy (CAA), cerebral hemorrhage, cerebral infarction, cognitive impairment, dementia, and/or Alzheimer's disease in a subject, said method comprising:
- administering, to a subject at risk of developing CAA, an antibody or antigen-binding fragment thereof that binds to GPIIIa49-66 on activated platelets, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:
- 1, a complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:
- 2, and a complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable region comprising a complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:
- 5, a complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:
- 6, and a complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:
- 7, wherein said administering is effective to inhibit formation of platelet micro-clots, thereby inhibiting the onset of CAA, cerebral hemorrhage, cerebral infarction, cognitive impairment, dementia, and/or Alzheimer's disease.
A method of inhibiting the onset of cerebral amyloid angiopathy (CAA), cerebral hemorrhage, cerebral infarction, cognitive impairment, dementia, and/or Alzheimer's disease in a subject, said method comprising:
- administering, to a subject at risk of developing CAA, a nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that binds to GPIIIa49-66 on activated platelets, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:
- 1, a complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:
- 2, and a complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable region comprising a complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:
- 5, a complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:
- 6, and a complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:
- 7, wherein said administering is effective to inhibit formation of platelet micro-clots, thereby inhibiting the onset of CAA, cerebral hemorrhage, cerebral infarction, cognitive impairment, dementia, and/or Alzheimer's disease.
A method of reducing cerebral vascular platelet micro-clots in a subject in need thereof, said method comprising:
- administering, to the subject having cerebral vascular platelet micro-clots, an antibody or antigen-binding fragment thereof that binds to GPIIIa49-66 on activated platelets, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:
- 1, a complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:
- 2, and a complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable region comprising a complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:
- 5, a complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:
- 6, and a complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:
- 7, wherein said administering is effective to dissolve and clear the cerebral vascular platelet micro-clots.
Dependencies are inferred from the claim text.